JP2022551691A5 - - Google Patents

Info

Publication number
JP2022551691A5
JP2022551691A5 JP2022521353A JP2022521353A JP2022551691A5 JP 2022551691 A5 JP2022551691 A5 JP 2022551691A5 JP 2022521353 A JP2022521353 A JP 2022521353A JP 2022521353 A JP2022521353 A JP 2022521353A JP 2022551691 A5 JP2022551691 A5 JP 2022551691A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
compounds
group
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2022521353A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551691A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/059377 external-priority patent/WO2021070054A1/en
Publication of JP2022551691A publication Critical patent/JP2022551691A/ja
Publication of JP2022551691A5 publication Critical patent/JP2022551691A5/ja
Ceased legal-status Critical Current

Links

JP2022521353A 2019-10-08 2020-10-06 ヒト免疫不全ウイルスの複製阻害剤 Ceased JP2022551691A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962912215P 2019-10-08 2019-10-08
US62/912,215 2019-10-08
PCT/IB2020/059377 WO2021070054A1 (en) 2019-10-08 2020-10-06 Inhibitors of human immunodeficiency virus replication

Publications (2)

Publication Number Publication Date
JP2022551691A JP2022551691A (ja) 2022-12-13
JP2022551691A5 true JP2022551691A5 (https=) 2023-10-17

Family

ID=72896013

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022521353A Ceased JP2022551691A (ja) 2019-10-08 2020-10-06 ヒト免疫不全ウイルスの複製阻害剤

Country Status (5)

Country Link
US (1) US20220370451A1 (https=)
EP (1) EP4041729B1 (https=)
JP (1) JP2022551691A (https=)
ES (1) ES2962774T3 (https=)
WO (1) WO2021070054A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
CN121335877A (zh) 2023-06-15 2026-01-13 Viiv保健英国第五有限公司 用于制备化合物的方法和中间体
TW202547514A (zh) 2024-02-05 2025-12-16 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
AU2012278976B2 (en) 2011-07-06 2017-05-11 Gilead Sciences, Inc. Compounds for the treatment of HIV
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
ES2642265T3 (es) 2013-01-09 2017-11-16 Gilead Sciences, Inc. Compuestos terapéuticos para el tratamiento de infecciones virales
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
EP3186239B1 (en) 2014-08-29 2018-10-10 Gilead Sciences, Inc. Antiretroviral agents
CN107151223B (zh) 2016-03-10 2020-03-31 中国医学科学院药物研究所 一类n-烷基吲哚类化合物在制备抗流感病毒药物中的用途
CN119462611A (zh) 2016-08-19 2025-02-18 吉利德科学公司 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
TW201906834A (zh) 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
JP7083398B2 (ja) 2018-02-15 2022-06-10 ギリアード サイエンシーズ， インコーポレイテッド ピリジン誘導体およびｈｉｖ感染を処置するためのその使用
EP3752496B1 (en) 2018-02-16 2023-07-05 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
EP3774775B8 (en) * 2018-04-11 2023-11-15 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
EP3849982A1 (en) * 2018-09-14 2021-07-21 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US11541055B2 (en) * 2018-10-24 2023-01-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
ES2971987T3 (es) * 2018-10-24 2024-06-10 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de inmunodeficiencia humana
JP7500555B2 (ja) * 2018-10-25 2024-06-17 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤
JP2022506399A (ja) * 2018-11-05 2022-01-17 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤
EP4038068A1 (en) * 2019-10-01 2022-08-10 VIIV Healthcare UK (No.5) Limited N-substituted-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl derivatives as inhibitors of the human immunodeficiency virus replication
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑
JP7703538B2 (ja) * 2019-12-09 2025-07-07 ヴィーブ、ヘルスケア、カンパニー カボテグラビルを含んでなる医薬組成物
BR112022020933A2 (pt) * 2020-04-15 2022-12-06 Viiv Healthcare Uk No 5 Ltd Inibidores de replicação do vírus da imunodeficiência humana

Similar Documents

Publication Publication Date Title
JP2022551691A5 (https=)
JP2021098728A5 (https=)
JP2021063088A5 (https=)
JP2024540183A5 (https=)
JP2024133474A5 (https=)
JP2022191257A5 (https=)
JP2022009090A5 (https=)
JP2022537047A5 (https=)
JP2021100937A5 (https=)
JP2023541432A5 (https=)
JP2022531251A5 (https=)
JP2023541430A5 (https=)
JP2022525013A5 (https=)
JP2005520778A5 (https=)
JP2006501240A5 (https=)
JP2020512337A5 (https=)
JP2022523726A5 (https=)
JP2018513188A5 (https=)
JP2002528502A5 (https=)
JP2019533660A5 (https=)
JP2022545156A5 (https=)
JP2017533972A5 (https=)
JP2019515909A5 (https=)
JP2024512425A5 (https=)
EP4494701A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases